Table 2.

Clinical, morphological, and mutational correlates of pseudoglands.

Factor	Total	Pseudoglands present	Pseudoglands negative	P (yes versus no pseudoglands)
Total	338	132 (39%)	206 (61%)
Gender				0.001
Male	231	104 (45% of gender)	127 (55%)
Female	107	28 (26%)	79 (74%)
Age (mean ± SD)
All	58.5 ± 13.8	59.5 ± 14.2	58.0 ± 13.4	0.31
Male	57.8 ± 12.9	59.4 ± 12.6	56.5 ± 13	0.10
Female	60.2 ± 15.3	60.0 ± 18.9	60.2 ± 14.0	0.96
Ethnicity				0.32 (grouped together: Hispanic, native American and not stated)
White	159	61	91
Asian	157	56	100
Black	14	8	5
Hispanic	10	5	5
Native American	1	0	1
Not stated	6	2	4
Tumor subtype				0.002392 (FLC and below grouped together)
NOS	275	116	152
Steatohepatitic	22	3	19
Scirrhous	21	2	16
Clear cell	14	3	11
FLC	6	5	2
Lymphocyte rich	3	1	2
Cirrhotomimmetic	3	2	1
Sarcomatoid	2	0	2
Myxoid	1	0	1
Tumor grade predominate				0.014
1	22	10	19
2	71	48	43
3	148	53	94
4	103	21	50
Tumor necrosis				0.002
Yes	69 (20%)	16 (12%)	53 (26%)
No	269 (80%)	116 (78%)	153 (74%)
Tumor hyaline bodies				0.155
Yes	43 (44%)	15	35
No	304	117	171
Tumor bile				<0.0001
Yes	79	64	15
No	288	68	191
Tumor inflammation				0.33
Yes	93	32	60
No	254	100	146
Tumor steatosis (>5%)				0.057
Yes	80 (24%)	24	56 (x%)
No	258	108	150
Tumor fibrosis				0.5
Yes	95	27	62
No	252	105	144
No. somatic mutations
All	166 ± 177	170 ± 172	167 ± 184	0.89
Male	179 ± 203	181 ± 189	177 ± 218	0.90
Female	141 ± 100	128 ± 69	150 ± 111	0.33
Any Wnt mutation (CTNNB1, AXIN, and APC)				<0.001
Yes	128	70	58
No	210	62	148
CTNNB1 mutation				<0.001
CTNNB1 mutation alone	88	55	33
CTNNB1 + AXIN/APC	6	3	3
No CTNNB1 mutation	244	74	170
AXIN mutation				0.34
AXIN mutation alone	26	7	19
AXIN + CTNNB1/APC	3	0	3
No AXIN mutation	309	125	184
CTNNB1 and or APC				<0.001
Yes	104	63	39
No	243	69	167